ORYZON Genomics

155 articles about ORYZON Genomics

• ORYZON to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

  5/30/2023

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today that it will present positive preclinical efficacy data of ORY-4001 in a CMT model at the 2023 Peripheral Nerve Society (PNS) Annual Meeting.

• ORYZON to Present Trial in Progress Phase Ib FRIDA Study at the Upcoming 2023 ASCO Annual Meeting

  5/17/2023

  Oryzon Genomics, S.A. today announced the presentation of the trial in progress (TIP) FRIDA poster entitled Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, to be held in-person from June 2-6, 2023 at the McCormick Place in Chicago, Illinois.

• ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2023

  5/10/2023

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent developments.

• ORYZON to Give Updates on Corporate Progress in May-June 2023

  5/9/2023

  Oryzon Genomics, S.A. announced that its management will give an update on corporate progress at several international events on May-June.

• ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder

  4/3/2023

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, announced today positive outcome from its planned, prespecified interim analysis of its Phase 2b trial, PORTICO, with vafidemstat for borderline personality disorder (BPD).

• ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-mutant Acute Myeloid Leukemia Patients

  3/15/2023

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced today the enrollment of the first patient in its Phase Ib trial of iadademstat in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia (AML) harboring a FMS-like tyrosine kinase mutation (FLT3mut+), at the Massachusetts General Hospital in Boston, US.

• ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology

  2/22/2023

  Oryzon Genomics, S.A. announced that it will host a virtual panel discussion, featuring Dr. Dyanna Phillips Domilici, Dr. med. Peter Hahn, and Dr. Olga Salamero, discussing the unmet medical needs in specific central nervous system and oncology diseases.

• ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022

  2/17/2023

  Oryzon Genomics, S.A. reported financial results for the fourth quarter ended December 31, 2022 and provided an update on recent developments.

• ORYZON to Give Updates on Corporate Progress in February-March

  2/6/2023

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events on February-March.

• ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas

  1/18/2023

  Oryzon Genomics, S.A. announced today the enrollment of the first patient in a Phase II collaborative study with iadademstat in patients with relapsed/refractory high grade neuroendocrine carcinomas (NEC).

• ORYZON to Give Updates on Corporate Progress in January 2023

  1/5/2023

  Oryzon Genomics, S.A. announced that its management will give an update on corporate progress at several international events in January.

• ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches

  12/16/2022

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the approval by the EU-intergovernmental organization EUREKA secretariat of funding for the BRAVE Project (Breaking immune Resistance of Advanced cancers by HERV-K Vaccination and Epigenetic modulation) under the Eurostars-3 program.

• ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients with First-line Treatment of Iadademstat and Azacitidine in Oral Presentation at ASH-2022

  12/12/2022

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents the final data from its Phase IIa ALICE trial, investigating iadademstat in combination with azacitidine in elderly or unfit patients with acute myeloid leukemia (AML), at the 64th American Society of Hematology (ASH) Annual Conference.

• ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

  11/9/2022

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the FDA has approved the Investigational New Drug (IND) application to initiate a Phase II collaborative study with iadademstat in patients with relapsed/refractory high grade neuroendocrine carcinomas (NEC).

• ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2022CNS

  11/2/2022

  Oryzon Genomics, S.A. reported financial results for the third quarter of 2022 and provided an update on recent developments.

• ORYZON to Give Updates on Corporate Progress in October

  10/3/2022

  Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in October.

• ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

  9/16/2022

  Oryzon Genomics, S.A. today presents initial preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP), in a oral communication at the 10th European Conference on Mental Health (ECMH), being held in Lisbon (Portugal) on September 13-16.

• ORYZON to Give Updates on Corporate Progress in September 2022

  9/8/2022

  Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that its management will give an update on corporate progress at several international events in September.

• ORYZON Collaborates with the CMT Research Foundation in the US

  7/26/2022

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), announced today the start of a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patient-led, non-profit organization focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease, to explore Oryzon’s histone deacetylase 6 (HDAC6) inhibitors.

• ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022

  7/22/2022

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first half of 2022 and provided an update on recent developments.